Tsveta Milanova Sells 2,872 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,872 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $27.02, for a total transaction of $77,601.44. Following the sale, the insider owned 34,793 shares in the company, valued at approximately $940,106.86. This represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tsveta Milanova also recently made the following trade(s):

• On Tuesday, December 30th, Tsveta Milanova sold 2,932 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88.

Agios Pharmaceuticals Trading Down 1.3%

AGIO stock opened at $28.16 on Friday. The firm’s 50-day moving average is $31.00 and its two-hundred day moving average is $35.76. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -4.02 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter last year, the business earned $16.22 earnings per share. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals in the first quarter worth approximately $40,000. First Horizon Corp purchased a new stake in Agios Pharmaceuticals in the 3rd quarter worth approximately $45,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares during the period. Quantbot Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at $79,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the first quarter worth $133,000.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday. Bank of America raised their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. HC Wainwright upped their target price on Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Finally, Leerink Partners increased their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, December 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $39.44.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.